Good News on Oxford’s COVID-19 Vaccine

The Forum at the Harvard T.H. Chan School of Public Health Race for the COVID-19 Vaccine

"The next step will be to see if this translates into protection from the disease itself", he added.

Co-author, Professor Sarah Gilbert (University of Oxford) stressed the importance of knowing how the Covid vaccine behaves in people over the age of 55, during a UK Science Media Centre briefing on Thursday. But British efforts, lead by the Oxford vaccine group, have not yielded public results as of yet.

The researchers said that two doses of CoronaVac at different concentrations and using different dosing schedules had goof tolerance and moderately immunogenic in healthy adults aged between 18-59 years.

"The Phase II interim data for AZD1222 suggests older individuals have lower reactogenicity whilst still maintaining a robust immune response", said Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D in a statement.

At home, Oxford researchers continue to work on their own promising development, but they don't foresee any imminent announcements.

Earlier this month, Australian manufacturer CSL kicked off production of 30 million doses of the Oxford-AstraZeneca vaccine, despite it still undergoing clinical trials. Pfizer developed its vaccine with German partner BioNTech.

Infectious disease specialists answer questions about COVID-19 vaccines including if results from clinical trials will hold up in the real world.


The one where they looked for any adverse safety issues in more than 500 people. T-cell response occurred within 14 days of the first dose of vaccination, and antibody response occurred within 28 days of the booster dose of vaccination.

Moderna and Pfizer have not yet published results from their studies in medical papers for review.

"Older adults are a priority group for COVID-19 vaccination, because they are at increased risk of severe disease, but we know that they tend to have poorer vaccine responses", Dr Maheshi Ramasamy, Investigator at the Oxford Vaccine Group and Consultant Physician, explained.

The results follow news this month from Pfizer Inc and BioNTech and from Moderna, as well as from Russian Federation, of experimental vaccines proving more than 90% effective, based on interim data from large, late-stage trials.

"We are optimistic that we'll be able to do that before Christmas, and obviously we'll share that with you as soon as we can at that point".

Pollard said there is no competition between the various research teams, because several vaccines will be needed to bring the global pandemic under control and allow life to return to normal.

Related:

Comments

Latest news

Feds set to release alarming new COVID-19 modelling in Canada
However, as the latest modelling presentation reads: "A stronger response is needed now to slow the spread of COVID-19".

Fired Cyber Chief Krebs
Krebs shared one tweet by Hammill that claimed Krebs was sacked "for refusing to lie" to the president. The American leader maintains the former Vice President did not win, and that he will prove it.

Azerbaijani army enters territory ceded by Armenian forces
Armenian forces occupied some 77 percent of Aghdam in 1993, forcibly displacing almost 200,000 Azerbaijanis from their homeland. A joint statement on the matter was made by the Azerbaijani president, Armenia's PM, and the president of Russian Federation .

Oxford Covid-19 vaccine shown to be safe in older adults
Professor Pollard added Oxford was "not in a rush" to provide results, and denied competition with their American colleagues. The immune responses reported in the study don't prove that the vaccine protects against infection with the coronavirus.

Ersan Ilyasova waived by Bucks
The Bucks re-acquired their own No. 60 pick from the New Orleans Hornets in the Jrue Holiday trade earlier this week. That deal was later reported to be off the table due to Bogdanovic wanting to test the free agency .

Other news